- Home
- GERN vs CSAN Comparison
GERN vs CSAN Comparison
Compare GERN & CSAN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GERN
- CSAN
- Stock Information
- Founded
- GERN 1990
- CSAN 1936
- Country
- GERN United States
- CSAN Brazil
- Employees
- GERN N/A
- CSAN N/A
- Industry
- GERN Biotechnology: Pharmaceutical Preparations
- CSAN Retail-Auto Dealers and Gas Stations
- Sector
- GERN Health Care
- CSAN Consumer Discretionary
- Exchange
- GERN Nasdaq
- CSAN Nasdaq
- Market Cap
- GERN 2.5B
- CSAN 2.8B
- IPO Year
- GERN 1996
- CSAN N/A
- Fundamental
- Price
- GERN $3.93
- CSAN $5.85
- Analyst Decision
- GERN Strong Buy
- CSAN
- Analyst Count
- GERN 10
- CSAN 0
- Target Price
- GERN $7.05
- CSAN N/A
- AVG Volume (30 Days)
- GERN 6.7M
- CSAN 1.1M
- Earning Date
- GERN 11-07-2024
- CSAN 11-13-2024
- Dividend Yield
- GERN N/A
- CSAN 5.98%
- EPS Growth
- GERN N/A
- CSAN N/A
- EPS
- GERN N/A
- CSAN 0.22
- Revenue
- GERN $29,480,000.00
- CSAN $7,655,547,290.00
- Revenue This Year
- GERN $32,021.10
- CSAN $314.09
- Revenue Next Year
- GERN $298.14
- CSAN N/A
- P/E Ratio
- GERN N/A
- CSAN $6.50
- Revenue Growth
- GERN 9199.68
- CSAN 3.43
- 52 Week Low
- GERN $1.64
- CSAN $5.57
- 52 Week High
- GERN $5.34
- CSAN $16.45
- Technical
- Relative Strength Index (RSI)
- GERN 46.32
- CSAN 29.12
- Support Level
- GERN $3.75
- CSAN $6.08
- Resistance Level
- GERN $4.05
- CSAN $6.69
- Average True Range (ATR)
- GERN 0.16
- CSAN 0.29
- MACD
- GERN -0.01
- CSAN -0.05
- Stochastic Oscillator
- GERN 39.13
- CSAN 13.66
About GERN Geron Corporation
Geron Corp is a clinical-stage biopharmaceutical company focused on the research and development of cancer treatments. The company's drug in development, Imelstat, is being tested for the treatment of myelodysplastic syndromes, which are disorders of the blood, and myelofibrosis, which is a rare blood cancer affecting bone marrow. The company earns revenue through collaboration agreements, milestones, royalties, and licensing arrangements. Geron possesses various rights to this drug. The company operates as a single segment being, the development of therapeutic products for oncology.
About CSAN Cosan S.A. ADS
Cosan SA engages in several services throughout the energy and logistics sectors. Its reportable segments are Raizen, Compass, Moove, Rumo, and Radar. It generates the majority of its revenue from Raizen which operates in the production, commercialization, origination, and trading of ethanol, bioenergy, resale, and trading of electricity, renewable sources, marketing, origination, and trading of sugar and fuels, and lubricant.